US Stock MarketDetailed Quotes
ALLO Allogene Therapeutics
- 3.040
- -0.330-9.79%
Close Apr 24 16:00 ET
- 3.040
- 0.0000.00%
Post 18:57 ET
519.00MMarket Cap-1454P/E (TTM)
3.420High3.030Low2.11MVolume3.370Open3.370Pre Close6.54MTurnover1.87%Turnover RatioLossP/E (Static)170.72MShares6.89052wk High1.01P/B342.40MFloat Cap2.23052wk Low--Dividend TTM112.63MShs Float55.000Historical High--Div YieldTTM11.57%Amplitude2.230Historical Low3.101Avg Price1Lot Size
About Allogene Therapeutics Company
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Company Profile
SymbolALLO
Company NameAllogene Therapeutics
Listing DateOct 11, 2018
Issue Price18.00
Founded2017
CEODr. David D. Chang, M.D.,PhD
MarketNASDAQ
Employees233
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address210 East Grand Avenue
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-4811
Phone1-650-457-2700
Websitehttp://www.allogene.com
Company Executives
- Name
- Position
- Salary
- Dr. David D. Chang, M.D.,PhD
- Director, Chief Executive Officer and President
- 14.80M
- Geoffrey M. Parker
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Timothy L. Moore
- Executive Vice President and Chief Technical Officer
- --
- Earl Douglas
- Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
- --
- Dr. Zachary Roberts, M.D.,PhD
- Executive Vice President, Research and Development
- --
- Dr. Arie S. Belldegrun, F.A.C.S.,M.D.
- Executive Chairman of the Board
- 9.81M
- Joshua A. Kazam
- Director
- 1.14M
- Dr. Franz Bernard Humer, PhD
- Independent Director
- 584.99K
- Deborah M. Messemer
- Independent Director
- 500.76K
- David Bonderman
- Lead Independent Director
- --
- Dr. Owen N. Witte, M.D.
- Independent Director
- 512.88K
- Elizabeth Barrett
- Independent Director
- 483.26K
- Todd B. Sisitsky
- Independent Director
- --
- Dr. Vicki L. Sato, PhD
- Independent Director
- 481.88K
- Dr. Stephen L. Mayo, PhD
- Independent Director
- 873.76K
- John DeYoung
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg